AC Immune SA (ACIU) - Pangali EV/EBITDA

The market value of the asset on GURU.Markets, which stands at 0.00 as illustrated on this chart, helps assess AC Immune (ACIU), a company integrating environmental standards and bioethics into drug development. The business relies on scientific alliances with pharmaceutical behemoths to combat dementia. Since the company is in the testing phase and lacks a stable cash flow, development is funded through external injections and grants.

Developing vaccines against Alzheimer's disease requires colossal capital expenditures and long-term financing. By analyzing the EV/EBITDA dynamics, an investor assesses the total enterprise value of AC Immune (ACIU) inclusive of net debt relative to operating profit. This chart reflects the speed of asset payback while preparing for partnerships with pharma behemoths. This allows for a determination of whether the asset is overvalued before the drugs enter the market.